ClinicalTrials.gg
CompletedNCT01946711Updated Apr 12, 2022Results posted

Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi

A Phase 1/2 interventional study of Budesonide and Budesonide in Rhinosinusitis and Chronic Polyposis, sponsored by Pari Pharma GmbH. Completed at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by Pari Pharma GmbH · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 21 studies in Rhinosinusitis with a site in Germany — 3 open to participants now, 7 under way, 4 of them phase 3. Rhinosinusitis · Germany.

Enrollment
14th of 15
14 · median 216
Started
2013
the only one that year
Phase 1/2
2 of 21
none open now
Registered
6th of 21
by date
Lead sponsor
2 of 21
Pari Pharma GmbH

Among the 21 studies in Rhinosinusitis with a site in Germany, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2013, is one of 2 in phase 1/2, and was the 6th registered.

Rhinosinusitis

252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

3 of the 21 studies in Rhinosinusitis with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Rhinosinusitis with a site in Germany, or all of them as a file.
02

Study summary

The study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the therapy of chronic rhinosinusitis (CRS) with polyposis nasi in adult patients. Ideally, the selected parameter should allow a correlation between an objective methodology and the clinical outcome of the study patients.

03

Conditions studied

  • Rhinosinusitis
  • Chronic Polyposis

Browse trials for

Keywords

  • CRS
  • polyposis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with confirmed diagnosis of chronic rhinosinusitis (CRS) with polyposis nasi grade I-III
  • Patient with a PNIF of > 7 l/min separated for left and right side of the nose
  • Patient's written
  • Male or female,>= 18 years of age
  • Patient is able to undergo nasal therapy without restrictions
  • Capable of understanding the purpose and risk of the clinical trial
  • Female patients with must have a negative urine pregnancy test prior to first IMP administration
  • Patient has completed correctly the diary during the Wash-in Phase

Exclusion criteria

Exclusion Criteria:

  • Patients with cystic fibrosis
  • Patients with polyposis nasi grade IV
  • Patients with prior sinonasal surgery (exemption: polypectomy)
  • Patients with primary ciliaritis
  • Pregnant or breastfeeding women
  • Patients with suspected active upper airway infection
  • Receipt of an drug as part of a clinical trial within 4 weeks prior to first administration of IMP
  • Drug or alcohol abuse
  • End-stage
  • Known to Budesonide
  • Patients with oral therapy within the last 4 weeks
  • Patients with frequent epistaxis (> 2 per month)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Buparid; Treatment A

    Buparid 1 mg budesonide/2 ml nebuliser solution

    Drug: Budesonide

  • Active comparator
    Budes; Treatment B

    Budes® Nasal Spray 50 µg budesonide/pump

    Drug: Budesonide

Interventions

06

What researchers measure

Primary outcomes

  1. Change of Inflammation of the Nasal Mucosa and Paranasal Sinus

    Inflammation of the nasal mucosa and paranasal sinus was assessed using the Lund-Mackay score based on magnetic resonance imaging. The score can take on values between 0 and 24 points, with higher values indicating more severe impairment. The outcome investigated is the intraindividual mean score of 2 independent raters assessing the same images.

    Time frame: Change from Baseline to Week 8

Secondary outcomes

  1. Safety Assessment

    Treatment-emergent adverse events (AEs) Each participant has been monitored for adverse events up to 26 weeks. All patients withdrawn from the study will be followed-up for AEs or SAEs for further 2 weeks or 4 weeks, respectively.

    Time frame: up to 26 weeks

Other outcomes

  1. Health-specific Quality of Life

    Health-specific quality of life was assessed by means of the self-rated, 22-item Sino-Nasal Outcome Test (SNOT-22). The SNOT-22 total score has a (theoretical) range of 0 - 110 points, with higher scores indicating more severe impairment. Presented are the mean values of the SNOT-22 total score after 24 weeks minus value at day 0 (baseline).

    Time frame: 24 weeks

  2. Nasal Obstruction

    Nasal obstruction was assessed using the method of rhinomanometry by measuring the positive nasal inspiratory flow (PNIF). For the assessment the subject had to inhale maximally through the nose three times and the highest value of flow rate was recorded after 4 weeks and 8 weeks of treatment.

    Time frame: 4 weeks / 8 weeks

07

Results

Posted Apr 12, 2022

Participant flow

4 patients not randomised

Participant flow — Overall Study
MilestoneBuparid; Treatment ABudes; Treatment B
Started86
Completed86
Not completed00

Outcome measures

PrimaryChange of Inflammation of the Nasal Mucosa and Paranasal Sinus

Inflammation of the nasal mucosa and paranasal sinus was assessed using the Lund-Mackay score based on magnetic resonance imaging. The score can take on values between 0 and 24 points, with higher values indicating more severe impairment. The outcome investigated is the intraindividual mean score of 2 independent raters assessing the same images.

Time frame:
Change from Baseline to Week 8
Reported as:
Median · units on a scale
Change of Inflammation of the Nasal Mucosa and Paranasal Sinus
units on a scaleBuparid; Treatment ABudes; Treatment B
Change of Inflammation of the Nasal Mucosa and Paranasal Sinus-2 (-3.5 to 2.5)-0.8 (-3.5 to 1)
SecondarySafety Assessment

Treatment-emergent adverse events (AEs) Each participant has been monitored for adverse events up to 26 weeks. All patients withdrawn from the study will be followed-up for AEs or SAEs for further 2 weeks or 4 weeks, respectively.

Time frame:
up to 26 weeks
Reported as:
Count of participants · Participants
Safety Assessment
ParticipantsBuparid; Treatment ABudes; Treatment B
Safety Assessment54
Other pre-specifiedHealth-specific Quality of Life

Health-specific quality of life was assessed by means of the self-rated, 22-item Sino-Nasal Outcome Test (SNOT-22). The SNOT-22 total score has a (theoretical) range of 0 - 110 points, with higher scores indicating more severe impairment. Presented are the mean values of the SNOT-22 total score after 24 weeks minus value at day 0 (baseline).

Time frame:
24 weeks
Reported as:
Mean · score on a scale
Health-specific Quality of Life
score on a scaleBuparid; Treatment ABudes; Treatment B
Health-specific Quality of Life23.6 (19.7 to 27.6)14.4 (9.8 to 18.9)
Other pre-specifiedNasal Obstruction

Nasal obstruction was assessed using the method of rhinomanometry by measuring the positive nasal inspiratory flow (PNIF). For the assessment the subject had to inhale maximally through the nose three times and the highest value of flow rate was recorded after 4 weeks and 8 weeks of treatment.

Time frame:
4 weeks / 8 weeks
Reported as:
Mean · ml/sec
Nasal Obstruction
ml/secBuparid; Treatment ABudes; Treatment B
Mean flow rate after 4 weeks746 (462 to 1031)574 (267 to 881)
Mean flow rate after 8 weeks755 (644 to 867)646 (527 to 765)

Adverse events

Collected over Each participant has been monitored for adverse events up to 48 weeks. All patients withdrawn from the study will be followed-up for AEs or SAEs for further 2 weeks or 4 weeks, respectively.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Buparid; Treatment A0/8 (0%)0/8 (0%)5/8 (62.5%)
Budes; Treatment B0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventBuparid; Treatment ABudes; Treatment B
Nasal DrynessRespiratory, thoracic and mediastinal disorders1/81/6
Sputum IncreasedRespiratory, thoracic and mediastinal disorders0/81/6
CoughRespiratory, thoracic and mediastinal disorders0/81/6
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders0/81/6
DepressionPsychiatric disorders0/81/6
Sensitive SkinSkin and subcutaneous tissue disorders0/81/6
Otitis mediaInfections and infestations0/81/6
NasopharyngitisInfections and infestations1/81/6
EpistaxisRespiratory, thoracic and mediastinal disorders1/80/6
ParosmiaNervous system disorders1/80/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Buparid; Treatment ABudes; Treatment BTotal
<=18 years000
Between 18 and 65 years8614
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Buparid; Treatment ABudes; Treatment BTotal
Female336
Male538
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Buparid; Treatment ABudes; Treatment BTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Buparid; Treatment ABudes; Treatment BTotal
Germany8614
08

Study locations

4 sites
  • University Göttingen
    Göttingen, 37075, Germany
  • UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • University LMU Munich
    Munich, 81377, Germany
  • HNO-Zentrum Mangfall-Inn
    Rosenheim, 83022, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2013 to primary completion in Feb 2020, 77 months.

Results were first posted in Apr 2022, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2013
First posted
Sep 20, 2013
StartActual
Aug 28, 2013
Primary completionActual
Feb 3, 2020
CompletionActual
Jun 21, 2021
Results first posted
Apr 12, 2022
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01946711
Lead sponsor
Pari Pharma GmbH
Responsible party
Sponsor
First posted
Sep 20, 2013
Start date
Aug 28, 2013
Primary completion
Feb 3, 2020
Completion
Jun 21, 2021
Results posted
Apr 12, 2022
Last update
Apr 12, 2022

Study contacts

Sven Becker, MD
principal investigator · Johannes Gutenberg University Mainz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion